Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/32089
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Loo, Sun | - |
dc.contributor.author | Lim, Andrew Boon Ming | - |
dc.contributor.author | Lee, Sze Ting | - |
dc.contributor.author | Grigg, Andrew P | - |
dc.date | 2022 | - |
dc.date.accessioned | 2023-02-07T05:52:01Z | - |
dc.date.available | 2023-02-07T05:52:01Z | - |
dc.date.issued | 2023 | - |
dc.identifier.citation | Clinical Lymphoma, Myeloma & Leukemia 2023; 23(3) | en_US |
dc.identifier.issn | 2152-2669 | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/32089 | - |
dc.description.abstract | In patients with relapsed/refractory lymphoma after first line therapy, chemosensitivity to salvage chemotherapy is the main determinant of outcome pre-autologous stem cell transplant . With novel therapies not yet widely available and poor responses to conventional dose salvage therapy such as ifosfamide, carboplatin, and etoposide (ICE) in patients with early relapse within 12 months and primary refractory disease, there is capacity to dose intensify ifosfamide and etoposide (augmented ICE). | en_US |
dc.language.iso | eng | - |
dc.subject | DLBCL | en_US |
dc.subject | Hodgkin | en_US |
dc.subject | Salvage therapy | en_US |
dc.subject | Transplant | en_US |
dc.title | Augmented ICE in Patients With Poor-Risk Refractory and Relapsed Lymphomas. | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | Clinical lymphoma, myeloma & leukemia | en_US |
dc.identifier.affiliation | Molecular Imaging and Therapy | en_US |
dc.identifier.affiliation | Clinical Haematology | en_US |
dc.identifier.doi | 10.1016/j.clml.2022.11.010 | en_US |
dc.type.content | Text | en_US |
dc.identifier.pubmedid | 36707275 | - |
local.name.researcher | Grigg, Andrew P | |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Clinical Haematology | - |
crisitem.author.dept | Molecular Imaging and Therapy | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
crisitem.author.dept | Clinical Haematology | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.